Leerink

Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy

6 Gene Therapy M&A Targets On The Radar

Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

6 Gene Therapy M&A Targets On The Radar

Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

Leerink Out Bullish On GW Pharma: 4 Reasons Why

Leerink: Improving Fundamentals Drive Teva Upgrade

Leerink Out Bullish On GW Pharma: 4 Reasons Why

Leerink: Improving Fundamentals Drive Teva Upgrade

Leerink Upgrades Mednax On Margin Expansion, Share Gains And Valuation

Leerink: Translate Bio's Cystic Fibrosis Candidate Could Generate $1.8B

Leerink Recent News

Wall Street Analysts Reflect On AT&T-Time Warner Ruling, Assess Implications Outside Tech, Media

Analysts Roar Praise For Aslan, But Leerink More Tepid

Leerink Downgrades Hologic After 'Lower Quality' Q2 Revenue Beat

Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms

Leerink's Takeaways From CNBC's 'Healthy Returns' Conference

Leerin: Armo Biosciences' 'Promising' Data Justifies A Bullish Stance

Why Leerink Adjusted Upside Expectations For 3 Biotechs

AbbVie Shares Double In A Year; Leerink Moves To Sidelines

Leerink: Bluebird Bio's Catalysts Are Priced In

The CVS-Aetna Deal: The Sell Side Responds

Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch

Buy Thermo Fisher On Amazon Fear-Inspired Dip

Express Scripts: Another Potential Amazon Victim?

Amazon Could Partner With UnitedHealth For Pharmacy Unit By Thanksgiving

Analyst: Amazon's Entry Into Pharmacy Is All But Certain At This Point

Selling The News In Acadia Pharmaceuticals

Pros And Cons Of All The News Out Of Acadia Pharma This Week

There's Good Cause To Be Excited About Amicus Therapeutics Clinical Program

What's The Thesis On ProQR Now, After Promising Phase 1 Data?

43% Upside Seen For Dova Pharma Following Competitor Product's Poor Results

The Street Has Finally Recognized The Exelixis Clinical Program Potential

Mirati Therapeutics Sitravatinib Data, Explained

Inside Align Technology's Q2 Beat And Raise: Teen Segment Could See An Inflection Point